Brookline Capital Acquisition Predicts CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Brookline Capital Acquisition raised their Q2 2026 earnings per share (EPS) estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, March 11th. Brookline Capital Acquisition analyst L. Cann now expects that the company will post earnings of ($1.16) per share for the quarter, up from their previous forecast of ($1.22). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Acquisition also issued estimates for CRISPR Therapeutics’ Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($4.96) EPS and FY2027 earnings at ($5.51) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same period in the previous year, the company posted ($1.01) earnings per share. The company’s quarterly revenue was down 97.8% compared to the same quarter last year.

A number of other research analysts have also weighed in on the stock. TD Cowen raised their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Evercore reaffirmed an “outperform” rating and issued a $74.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, February 13th. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Finally, Citizens Jmp cut their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Price Performance

CRSP opened at $48.75 on Friday. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.72. The firm’s fifty day moving average price is $54.10 and its two-hundred day moving average price is $57.24.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GSK plc bought a new stake in CRISPR Therapeutics in the 4th quarter valued at about $168,890,000. Orbis Allan Gray Ltd increased its stake in shares of CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares in the last quarter. Geode Capital Management LLC raised its position in shares of CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock valued at $100,789,000 after purchasing an additional 1,025,979 shares during the period. SR One Capital Management LP raised its position in shares of CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock valued at $132,132,000 after purchasing an additional 989,812 shares during the period. Finally, State Street Corp lifted its stake in shares of CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the completion of the sale, the chief executive officer owned 134,201 shares in the company, valued at $8,082,926.23. This trade represents a 30.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,800 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total transaction of $147,840.00. Following the completion of the sale, the general counsel directly owned 87,815 shares in the company, valued at $4,636,632. This trade represents a 3.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 111,677 shares of company stock valued at $6,308,848 over the last three months. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: management reported $116M in FY‑25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer‑term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near‑term EPS adjustments (slightly less negative for FY‑2026/FY‑2027), a modest constructive signal for near‑term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most‑searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short‑interest data appears noisy: recent feeds show inconsistent/zero short‑interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell‑off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near‑term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi‑percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.